MX2022008055A - Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas. - Google Patents

Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.

Info

Publication number
MX2022008055A
MX2022008055A MX2022008055A MX2022008055A MX2022008055A MX 2022008055 A MX2022008055 A MX 2022008055A MX 2022008055 A MX2022008055 A MX 2022008055A MX 2022008055 A MX2022008055 A MX 2022008055A MX 2022008055 A MX2022008055 A MX 2022008055A
Authority
MX
Mexico
Prior art keywords
ascorbic acid
quinone
chagas disease
compounds
treatment
Prior art date
Application number
MX2022008055A
Other languages
English (en)
Inventor
Sueli De Oliveira Silva Lautenschlager
Vânia Cristina Desoti
Celso Vataru Nakamura
Valdecir Farias Ximenes
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of MX2022008055A publication Critical patent/MX2022008055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporciona un método para tratar, prevenir o aliviar uno o más síntomas de enfermedad de Chagas en un sujeto, que comprende administrarle al sujeto (i) ácido ascórbico, o un enantiómero simple, una mezcla de enantiómeros, o una mezcla de diastereómeros de este; o una sal, solvato o hidrato farmacéuticamente aceptable de este; y (ii) un compuesto de quinona, o un enantiómero simple, una mezcla de enantiómeros, o una mezcla de diastereómeros de este; o una sal, solvato, hidrato o profármaco farmacéuticamente aceptable de este.
MX2022008055A 2016-12-06 2019-06-05 Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas. MX2022008055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430758P 2016-12-06 2016-12-06

Publications (1)

Publication Number Publication Date
MX2022008055A true MX2022008055A (es) 2022-07-27

Family

ID=62491595

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019006593A MX2019006593A (es) 2016-12-06 2017-12-05 Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.
MX2022008055A MX2022008055A (es) 2016-12-06 2019-06-05 Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019006593A MX2019006593A (es) 2016-12-06 2017-12-05 Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.

Country Status (9)

Country Link
US (2) US11998523B2 (es)
AR (1) AR110317A1 (es)
CL (1) CL2019001529A1 (es)
CO (1) CO2019007158A2 (es)
CR (1) CR20190323A (es)
EC (1) ECSP19048402A (es)
MX (2) MX2019006593A (es)
PE (1) PE20191745A1 (es)
WO (1) WO2018106623A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
CA2689717C (en) 2006-06-16 2016-10-18 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
WO2011011317A1 (en) 2009-07-20 2011-01-27 Summa Health System Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant
WO2012012370A1 (en) 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
ES2811674B2 (es) 2018-06-06 2024-02-07 Ic Medtech Corp Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria

Also Published As

Publication number Publication date
WO2018106623A1 (en) 2018-06-14
ECSP19048402A (es) 2019-09-30
MX2019006593A (es) 2019-09-13
US20240398755A1 (en) 2024-12-05
US20190343794A1 (en) 2019-11-14
US11998523B2 (en) 2024-06-04
CL2019001529A1 (es) 2019-11-08
CO2019007158A2 (es) 2019-10-09
BR112019011789A2 (pt) 2019-10-29
CR20190323A (es) 2019-11-11
AR110317A1 (es) 2019-03-20
PE20191745A1 (es) 2019-12-12

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
SV2018005742A (es) Inhibidores de mcl-1 macrocíclicos para tratar el cáncer
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
MX2019000451A (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
UY37569A (es) Inhibidores del inmunoproteasoma
UY35903A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer